

IN THE CLAIMS

1 (Withdrawn): A compound which inhibits the activation of a gene by NF- κ B.

2 (Withdrawn): The compound of Claim 1, which is a nucleic acid or a nucleic acid analog.

3 (Withdrawn): The compound of Claim 1 which is a nucleic acid or nucleic acid analog which comprises the consensus sequence of the NF- κ B binding site.

4 (Withdrawn): The compound of Claim 1 which is a nucleic acid or nucleic acid analog which comprises the base sequence of SEQ ID NO: 1.

5 (Previously Presented): A method for treating a brain disorder comprising administering to a subject in need thereof an effective amount of a composition comprising:

a compound which inhibits the activation of a gene by NF- κ B and which is a nucleic acid or nucleic acid analog which comprises a consensus sequence of the NF- κ B binding site, and

a carrier.

6 (Previously Presented): The method of Claim 5, wherein said carrier is a liposome.

7 (Previously Presented): The method of Claim 5, wherein said carrier is a cationic liposome.

8 (Previously Presented): The method of Claim 5, wherein said carrier is a liposome comprising a membrane fusion promoter.

9 (Previously Presented): The method of Claim 5, wherein said compound is a nucleic acid or a nucleic acid analog.

10 (Previously Presented): The method of Claim 5, wherein said compound is DNA.

11 (Previously Presented): The method of Claim 5, wherein said compound is a nucleic acid or nucleic acid analog which comprises the base sequence of SEQ ID NO: 1.

12 (Previously Presented): The method of Claim 5, wherein said compound is a double-stranded nucleic acid or nucleic acid analog.

13 (Previously Presented): The method of Claim 5, wherein said compound is a cyclic nucleic acid or nucleic acid analog.

14 (Previously Presented): The method of Claim 5, wherein said compound comprises an S-oligonucleotide, an oligonucleotide in which one or more methyl phosphate group(s) carrying no charge has (have) been substituted for the phosphodiester bond, an acylated oligonucleotide, or an alkylated oligonucleotide, comprising the base sequence of SEQ ID NO: 1.

15 (Previously Presented): The method of Claim 5, wherein said compound comprises several units of a double-stranded nucleic acid or nucleic acid analog, which comprises the consensus sequence of the NF- κ B binding site.

16 (Previously Presented): The method of Claim 5, wherein said composition is administered intracisternally.

17 (Previously Presented): The method of Claim 5, wherein said composition is administered in a dose ranging from 10 to 10,000 nmoles.

18 (Withdrawn): A liposome comprising a compound which inhibits the activation of a gene by NF- κ B.

19 (Withdrawn): The liposome of Claim 18 that comprises a cationic lipid.

Appl. No.: 10/677,301
In reply to Office Action of July 13, 2005

20 (Withdrawn): The liposome of Claim 18 that comprises a membrane-fusion promoter.

21 (Withdrawn): The liposome of Claim 18 that comprises a large unilamellar vesicle (LUV) structure.

22 (Withdrawn): The liposome of Claim 18 that comprises a multilamellar vesicle (MLV) structure.

23 (Withdrawn): The liposome of Claim 18 that comprises a small unilamellar vesicle (SUV) structure.